

Zujiang Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3114173/publications.pdf>

Version: 2024-02-01

80
papers

3,000
citations

257450

24
h-index

189892

50
g-index

88
all docs

88
docs citations

88
times ranked

4202
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 1014-1023.	12.1	498
2	Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1003-1011.	7.0	334
3	A Metal-Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy. <i>Advanced Materials</i> , 2020, 32, e1906024.	21.0	300
4	Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. <i>Gut</i> , 2021, 70, 1253-1265.	12.1	168
5	Mesenchymal Stem Cell/Red Blood Cell-Inspired Nanoparticle Therapy in Mice with Carbon Tetrachloride-Induced Acute Liver Failure. <i>ACS Nano</i> , 2018, 12, 6536-6544.	14.6	109
6	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 55.	3.7	97
7	A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. <i>Advanced Science</i> , 2020, 7, 2001435.	11.2	89
8	Alterations of the Human Gut Microbiome in Chronic Kidney Disease. <i>Advanced Science</i> , 2020, 7, 2001936.	11.2	82
9	LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 101, 19-28.	2.8	76
10	Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis. <i>Small</i> , 2020, 16, e1905233.	10.0	72
11	Role of MicroRNA-1 in Human Cancer and Its Therapeutic Potentials. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	61
12	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , 2016, 14, 4042-4048.	2.4	61
13	Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. <i>Oncotarget</i> , 2016, 7, 38333-38346.	1.8	54
14	Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 15083.	3.3	49
15	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1573-1582.	3.8	45
16	Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth. <i>Scientific Reports</i> , 2015, 5, 10433.	3.3	43
17	Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. <i>Cancer Cell International</i> , 2019, 19, 211.	4.1	41
18	Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 342.	3.9	39

#	ARTICLE	IF	CITATIONS
19	Overexpression of Pyruvate Dehydrogenase E1 α Subunit Inhibits Warburg Effect and Induces Cell Apoptosis Through Mitochondria-Mediated Pathway in Hepatocellular Carcinoma. <i>Oncology Research</i> , 2019, 27, 407-414.	1.5	38
20	Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. <i>Hepatology Research</i> , 2019, 49, 1097-1108.	3.4	37
21	Circular RNA hsa_circ_0056836 functions as an oncogenic gene in hepatocellular carcinoma through modulating miR-766-3p/FOSL2 axis. <i>Aging</i> , 2020, 12, 2485-2497.	3.1	32
22	Long intergenic noncoding RNA SNHG16 interacts with miR-195 to promote proliferation, invasion and tumorigenesis in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2019, 383, 111501.	2.6	31
23	MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF- β 2/Smad3 signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 107, 168-176.	5.6	30
24	miR-450b-5p loss mediated KIF26B activation promoted hepatocellular carcinoma progression by activating PI3K/AKT pathway. <i>Cancer Cell International</i> , 2019, 19, 205.	4.1	28
25	Characteristic of 523 COVID-19 in Henan Province and a Death Prediction Model. <i>Frontiers in Public Health</i> , 2020, 8, 475.	2.7	26
26	miR-96 exerts carcinogenic effect by activating AKT/GSK-3 β /E-catenin signaling pathway through targeting inhibition of FOXO1 in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 38.	4.1	25
27	Ammonia-induced energy disorders interfere with bilirubin metabolism in hepatocytes. <i>Archives of Biochemistry and Biophysics</i> , 2014, 555-556, 16-22.	3.0	24
28	Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 58.	2.7	24
29	miR-346 Promotes HCC Progression by Suppressing Breast Cancer Metastasis Suppressor 1 Expression. <i>Oncology Research</i> , 2018, 26, 1073-1081.	1.5	22
30	PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2017, 16, 4475-4482.	2.4	21
31	Metabolomic Analysis of the Effects of Adipose-Derived Mesenchymal Stem Cell Treatment on Rats With Sepsis-Induced Acute Lung Injury. <i>Frontiers in Pharmacology</i> , 2020, 11, 902.	3.5	21
32	Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-17.	1.3	21
33	Switching from Fatty Acid Oxidation to Glycolysis Improves the Outcome of Acute-on-Chronic Liver Failure. <i>Advanced Science</i> , 2020, 7, 1902996.	11.2	20
34	MicroRNA-638 induces apoptosis and autophagy in human liver cancer cells by targeting enhancer of zeste homolog 2 (EZH2). <i>Environmental Toxicology and Pharmacology</i> , 2021, 82, 103559.	4.0	20
35	Transcriptome-Wide 5-Methylcytosine Functional Profiling of Long Non-Coding RNA in Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 6877-6885.	1.9	19
36	Light-triggered NO-releasing nanoparticles for treating mice with liver fibrosis. <i>Nano Research</i> , 2020, 13, 2197-2202.	10.4	18

#	ARTICLE	IF	CITATIONS
37	A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. <i>EBioMedicine</i> , 2021, 67, 103389.	6.1	18
38	A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. <i>Hepatology International</i> , 2012, 6, 441-448.	4.2	17
39	Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2021, 116, 1676-1685.	0.4	16
40	Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 656674.	3.9	16
41	Protective effects of cilostazol on ethanol-induced damage in primary cultured hepatocytes. <i>Cell Stress and Chaperones</i> , 2018, 23, 203-211.	2.9	15
42	PRRC2A Promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1495-1511.	3.7	15
43	TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF- β signaling-mediated VEGF expression. <i>Cancer Management and Research</i> , 2019, Volume 11, 767-775.	1.9	14
44	Hepatic injury is associated with cell cycle arrest and apoptosis with alteration of cyclin A and D1 in ammonium chloride-induced hyperammonemic rats. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 427-434.	1.8	13
45	Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. <i>Journal of Cancer</i> , 2020, 11, 132-141.	2.5	13
46	The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer. <i>Tumor Biology</i> , 2016, 37, 6881-6891.	1.8	12
47	A novel predicted model for hypertension based on a large cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 10615.	3.3	12
48	The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study. <i>Arthritis Research and Therapy</i> , 2020, 22, 159.	3.5	11
49	Dysbiosis in the Human Microbiome of Cholangiocarcinoma. <i>Frontiers in Physiology</i> , 2021, 12, 715536.	2.8	11
50	Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 23.	3.7	10
51	Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis. <i>Lancet</i> , The, 2021, 397, 1213.	13.7	10
52	Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1060-1074.	1.6	9
53	Vaccinia virus expressing IL- β promotes antitumor immune responses in hepatocellular carcinoma. <i>Cell Biochemistry and Function</i> , 2019, 37, 618-624.	2.9	9
54	The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma. <i>Discovery Medicine</i> , 2015, 20, 311-24.	0.5	9

#	ARTICLE	IF	CITATIONS
55	RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 686547.	3.7	8
56	Dynamic changes in CD45RA ⁺ Foxp3 ^{high} regulatory T-cells in chronic hepatitis C patients during antiviral therapy. <i>International Journal of Infectious Diseases</i> , 2016, 45, 5-12.	3.3	7
57	Hepatitis B virus X protein promotes proliferation of hepatocellular carcinoma cells by upregulating miR-181b by targeting INC5. <i>Biological Chemistry</i> , 2018, 399, 611-619.	2.5	7
58	Expression and clinical significance of miR-3615 in hepatocellular carcinoma. <i>Journal of International Medical Research</i> , 2021, 49, 030006052098154.	1.0	7
59	In vitro effects of mitomycin C on the proliferation of the non-small-cell lung cancer line A549. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 20516-23.	1.3	7
60	Poly (ADP-ribose) polymerase- and cytochrome c-mediated apoptosis induces hepatocyte injury in a rat model of hyperammonia-induced hepatic failure. <i>Molecular Medicine Reports</i> , 2015, 11, 4211-4219.	2.4	5
61	The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 2215.	2.0	5
62	A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00033.	2.5	5
63	Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2020, 9, 1254-1262.	2.8	5
64	Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 122, 983.	2.6	5
65	Lowering blood ammonia prevents hepatocyte injury and apoptosis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 12347-55.	1.3	4
66	<p>Tumor suppressive functions of LZTFL1 in hepatocellular carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5537-5544.	2.0	3
67	Disturbance of hepatocyte growth and metabolism in a hyperammonemia microenvironment. <i>Archives of Biochemistry and Biophysics</i> , 2022, 716, 109109.	3.0	3
68	The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α -2b. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2015, 28, 1493-7.	0.2	3
69	Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected With Delta or Omicron Variants. <i>Journal of Infectious Diseases</i> , 2022, 226, 1120-1122.	4.0	3
70	The successful treatment for cardiac tamponade during radiofrequency ablation of hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 90-92.	1.3	2
71	Development of a Novel Simple Model to Predict Mortality in Patients With Systemic Lupus Erythematosus Admitted to the Intensive Care Unit. <i>Frontiers in Medicine</i> , 2021, 8, 689871.	2.6	2
72	Correlations between stemness indices for hepatocellular carcinoma, clinical characteristics, and prognosis. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5496-5510.	0.0	2

#	ARTICLE	IF	CITATIONS
73	Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-15.	1.3	2
74	Overlapping infection of <i>Nocardia farcinica</i> and <i>Aspergillus fumigatus</i> in a child with X-linked chronic granulomatous disease: a case report. <i>BMC Infectious Diseases</i> , 2022, 22, 69.	2.9	2
75	Analysis of Multi-Layer RNA Modification Patterns for the Characterization of Tumor Immune Microenvironment in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 761391.	3.7	1
76	Heparin inhibits burn-induced spleen cell apoptosis by suppressing interleukin-1 expression. <i>Chinese Medical Journal</i> , 2014, 127, 2463-9.	2.3	1
77	NH ₄ Cl affects the expression of Wnt/ β ² -catenin pathway in hepatocytes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 281-286.	1.4	0
78	Identifying drug candidates for hepatocellular carcinoma based on differentially expressed genes. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2664-2674.	0.0	0
79	Clinical characteristics, outcome and prognostic factors in critically ill patients with lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
80	Clinical characteristics, outcome and prognostic factors in critically ill patients with lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 514-521.	0.8	0